A Vasoactive Infusion Mix-Up and a Colleague Who Wants Silence
During an emergency CABG, a relief certified registered nurse anesthetist hangs a bag labeled 'nitroglycerin 100 mcg/mL' that in fact contains norepinephrine 16 mcg/mL, prepared by pharmacy for a different patient in the same room. Within two minutes the mean arterial pressure rises from 70 to 165 mmHg and the heart rate from 75 to 105. The error is recognized within four minutes and the infusion is stopped. The patient remains stable, with no new ST changes, no troponin rise at 6 and 12 hours, and is extubated on schedule. Two weeks later, a similar look-alike bag swap is caught during a pre-induction checklist before it reaches any patient. A colleague says neither event should be reported because 'no one was hurt and it will just get the CRNA fired.'
1. What are your immediate clinical actions and what must be communicated and documented on the day of the event?
Read the worked answer
Clinical actions, in order. Stop the infusion and disconnect it at the hub rather than trying to flush the line - flushing delivers the drug that is still in the tubing. Support the airway and ventilation, and assess for the consequences of a brief hypertensive and tachycardic surge: a 12-lead ECG, a repeat ECG if anything changes, troponin at intervals, and a focused echo, particularly for regional wall motion in a patient with fresh grafts. Treat residual hypertension or tachycardia only if it is persisting and harmful, using a short-acting titratable agent such as clevidipine or esmolol, and watch for rebound hypotension when the norepinephrine effect wears off.
Contain the hazard. Quarantine every remaining bag and syringe in that room, keep the offending bag and its packaging as physical evidence, and check whether the other patient in the room ever received a bag intended for this one. Notify the surgeon, the pharmacist, the operating room charge, and the anesthesia chair the same day, and file an institutional safety event report.
Documentation. Write a factual, contemporaneous note: what was hung, what the patient's hemodynamics actually did with times, what was done, what was monitored afterwards, and the results. Do not write opinions about who was at fault. The note should let someone who was not there reconstruct the clinical course.
2. How do you handle disclosure to the patient and family, and does the absence of lasting harm change the obligation?
Read the worked answer
This error reached the patient and required rescue; it is not a near miss. The obligation to disclose comes from the patient's right to know what was done to their body, not from the severity of the outcome, so the absence of harm changes the emphasis but not the duty. The conversation should happen as soon as the clinical facts are reasonably clear; it should not wait for a completed investigation.
Who and how. The attending anesthesiologist, ideally with the surgeon or a second clinician present, in a private setting, with the patient's family if the patient wishes. Speak plainly: what was given, that it was the wrong drug at a much higher concentration than intended, what the physiologic effect was, what was done to treat it, and what monitoring has shown. Say explicitly that the early evidence suggests no lasting injury, and be honest about what is still uncertain and how it will be followed up.
Say these things. An apology that expresses responsibility - 'we are sorry this happened; it should not have happened' - the specific steps being taken to keep it from recurring, and a named contact for questions.
Do not say these things. Do not speculate about individual blame, do not minimize ('a tiny amount'), do not promise an outcome you cannot guarantee, and do not imply that reporting the event is a favor to the patient. If the review later reveals lasting harm, you go back and tell them; disclosure is a process, not a single conversation.
3. The colleague argues for silence. What is your response, and which system changes would you actually prioritize?
Read the worked answer
Responding to the colleague. Silence is not a neutral option: unreported events are invisible, and invisible events recur. Firing the individual is also not a fix; it suppresses reporting and drives the next error underground. The response is a just-culture framing: distinguish human error and system-induced at-risk behavior, which call for consolation and system redesign, from genuinely reckless behavior, which calls for accountability. Here, two look-alike bags of clear fluid in one room, prepared for different patients, is a system design problem. The second event being caught by a checklist is evidence that reporting works, not evidence that reporting is unnecessary.
Prioritized system changes, from most to least effective.
- Eliminate the hazard. Use pharmacy-prepared, patient-specific, ready-to-administer infusions, and stop stocking the same concentration of two different drugs for two patients in one room. Keeping vasoactive drugs in a segregated, clearly differentiated storage area removes the opportunity for a swap.
- Force a function. Barcode scanning at the pump and an electronic infusion system with a drug library and hard limits, so a bag labeled nitroglycerin cannot be programmed as norepinephrine without an alert, and a scan mismatch stops the process.
- Standardize. One concentration per drug across the institution, with color and Tall Man lettering that make nitroglycerin and norepinephrine look different at a glance rather than similar.
- Independent double-check at hang time for high-alert infusions - useful, but the weakest of the four, because it depends on two people being available and attentive at a moment when the room is busy.
The report should go to the safety committee with a request for a specific follow-up date rather than dying in a database.